Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 35.64 kCr |
| Price/Earnings (Trailing) | 35.14 |
| Price/Sales (Trailing) | 6.69 |
| EV/EBITDA | 24.04 |
| Price/Free Cashflow | 36.58 |
| MarketCap/EBT | 27.42 |
| Enterprise Value | 35.75 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 2.5% |
| Price Change 1M | 0.00% |
| Price Change 6M | 9.5% |
| Price Change 1Y | 5.7% |
| 3Y Cumulative Return | 33.8% |
| 5Y Cumulative Return | 18.7% |
| 7Y Cumulative Return | 23.8% |
| 10Y Cumulative Return | 12.7% |
| Revenue (TTM) |
| 5.33 kCr |
| Rev. Growth (Yr) | 19% |
| Earnings (TTM) | 1.01 kCr |
| Earnings Growth (Yr) | 17.6% |
Profitability | |
|---|---|
| Operating Margin | 24% |
| EBT Margin | 24% |
| Return on Equity | 23.51% |
| Return on Assets | 17.89% |
| Free Cashflow Yield | 2.73% |
| Cash Flow from Investing (TTM) | -376.52 Cr |
| Cash Flow from Operations (TTM) | 1.16 kCr |
| Cash Flow from Financing (TTM) | -733.41 Cr |
| Cash & Equivalents | 89.81 Cr |
| Free Cash Flow (TTM) | 839.31 Cr |
| Free Cash Flow/Share (TTM) | 67.19 |
Balance Sheet | |
|---|---|
| Total Assets | 5.67 kCr |
| Total Liabilities | 1.36 kCr |
| Shareholder Equity | 4.32 kCr |
| Current Assets | 3.39 kCr |
| Current Liabilities | 1.16 kCr |
| Net PPE | 1.74 kCr |
| Inventory | 812.14 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.04 |
| Debt/Equity | 0.05 |
| Interest Coverage | 64.59 |
| Interest/Cashflow Ops | 46.81 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 28 |
| Dividend Yield | 0.98% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | -2.5% |
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: Outperforming stock! In past three years, the stock has provided 33.8% return compared to 13.2% by NIFTY 50.
Profitability: Very strong Profitability. One year profit margin are 19%.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Growth: Good revenue growth. With 37.8% growth over past three years, the company is going strong.
No major cons observed.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: Outperforming stock! In past three years, the stock has provided 33.8% return compared to 13.2% by NIFTY 50.
Profitability: Very strong Profitability. One year profit margin are 19%.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Growth: Good revenue growth. With 37.8% growth over past three years, the company is going strong.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.98% |
| Dividend/Share (TTM) | 28 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 81.18 |
Financial Health | |
|---|---|
| Current Ratio | 2.93 |
| Debt/Equity | 0.05 |
Technical Indicators | |
|---|---|
| RSI (14d) | 72.28 |
| RSI (5d) | 68.02 |
| RSI (21d) | 50.73 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Sell |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated May 5, 2025
Despite strong financial results, Ajanta Pharma's shares fell by 2.65% to Rs 2,691.90 by market close.
Market concerns seem to overshadow the positive earnings reported by Ajanta Pharma.
The decline in share price raises questions about investor confidence despite the robust performance.
Summary of Ajanta Pharma's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Ajanta Pharma ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Yogesh M Agrawal, trustee Yogesh Agrawal Trust | 14.47% |
| Rajesh M Agrawal, trustee Rajesh Agrawal Trust | 14.47% |
| Ravi P Agrawal, trustee Ravi Agrawal Trust | 13% |
| Aayush M Agrawal, trustee Aayush Agrawal Trust | 11.3% |
| Gabs Investments Pvt Ltd | 10.08% |
| Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund | 2.84% |
Detailed comparison of Ajanta Pharma against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.07 LCr | 58.94 kCr | -4.90% | -2.70% | 37.25 | 6.9 | - | - |
| CIPLA | Cipla | 1.07 LCr | 29.37 kCr |
Comprehensive comparison against sector averages
AJANTPHARM metrics compared to Pharmaceuticals
| Category | AJANTPHARM | Pharmaceuticals |
|---|---|---|
| PE | 35.14 | 33.54 |
| PS | 6.69 | 4.66 |
| Growth | 14.8 % | 9.1 % |
Ajanta Pharma is a prominent pharmaceuticals company headquartered in Mumbai, India. Operating under the stock ticker AJANTPHARM, the company boasts a market capitalization of Rs. 34,665.6 Crores.
As a specialty pharmaceutical formulation company, Ajanta Pharma, along with its subsidiaries, focuses on the development, manufacturing, and marketing of specialty pharmaceutical finished dosages. The company serves a diverse range of therapeutic segments, including:
Ajanta Pharma offers a wide array of pharmaceutical products, which include tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company operates not only in India but also extends its services across Africa, the rest of Asia, the United States, and various international markets.
Founded in 1973, Ajanta Pharma has demonstrated notable financial success, with a trailing 12 months revenue of Rs. 4,643.7 Crores. The company is also committed to returning value to its investors, offering a dividend yield of 1.95% per year. In the last 12 months, shareholders received a dividend of Rs. 54 per share. Furthermore, Ajanta Pharma has engaged in buybacks, having repurchased 0.8% of its own stock last year, contributing to the stability of its share price.
With a reported profit of Rs. 897.9 Crores over the past four quarters and a 40% revenue growth over the last three years, Ajanta Pharma continues to establish itself as a profitable and thriving player in the pharmaceutical industry.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
AJANTPHARM vs Pharmaceuticals (2021 - 2026)
Ajanta Pharma reported an 11% increase in profit after tax for Q4 FY2024-2025, reaching Rs 225 crore.
Earnings Call Transcript • 05 Feb 2026 Pls find enclosed Earnings Call Transcript |
General • 02 Feb 2026 Pls find enclosed intimation w.r.t Participation in Investor Conference |
Newspaper Publication • 02 Feb 2026 Pls find enclosed newspaper cuttings of Financial results published. |
General • 30 Jan 2026 Pls find enclosed Intimation of vesting of SARs and cancellation of ESOPs |
Analyst / Investor Meet • 30 Jan 2026 Pls find enclosed Audio recording of Earnings call conducted on 30th January 2026 |
Acquisition • 13 Jan 2026 Pls find enclosed herewith Intimation w.r.t Formation of Subsidiary |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
| Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal | 2.68% |
| Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110 | 1.81% |
| Canara Robeco Mutual Fund A/C Canara Robeco Large And Mid Cap Fund | 1.74% |
| Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Midcap Fund | 1.06% |
| Ravi P Agrawal | 0.23% |
| Aayush M Agrawal | 0.02% |
| Mannalal B. Agrawal | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| -9.40% |
| -9.60% |
| 23.62 |
| 3.66 |
| - |
| - |
| DRREDDY | Dr. Reddy's Lab | 1.04 LCr | 36.09 kCr | -0.10% | +0.40% | 18.56 | 2.87 | - | - |
| LUPIN | Lupin | 99.29 kCr | 25.03 kCr | -1.80% | -0.50% | 22.94 | 3.97 | - | - |
| AUROPHARMA | Aurobindo Pharma | 69.17 kCr | 33.03 kCr | -3.60% | -0.10% | 20.21 | 2.09 | - | - |
| -2.9% |
| 1,041 |
| 1,072 |
| 998 |
| 919 |
| 869 |
| 916 |
| Profit Before exceptional items and Tax | 5.3% | 359 | 341 | 331 | 269 | 307 | 290 |
| Total profit before tax | 5.3% | 359 | 341 | 331 | 269 | 307 | 290 |
| Current tax | 11.7% | 87 | 78 | 74 | 62 | 95 | 76 |
| Deferred tax | -331.1% | -2.05 | 2.32 | 2.29 | -17.81 | -20.34 | -2.35 |
| Total tax | 5% | 85 | 81 | 76 | 44 | 75 | 74 |
| Total profit (loss) for period | 5.4% | 274 | 260 | 255 | 225 | 233 | 216 |
| Other comp. income net of taxes | -79.3% | 2.51 | 8.3 | 0.16 | 2.04 | 1.44 | 5.71 |
| Total Comprehensive Income | 3% | 276 | 268 | 256 | 227 | 234 | 222 |
| Earnings Per Share, Basic | 5.4% | 21.91 | 20.83 | 20.44 | 18 | 18.6 | 17.27 |
| Earnings Per Share, Diluted | 5.5% | 21.91 | 20.82 | 20.43 | 18 | 18.59 | 17.26 |
| 21.2% |
| 1,011 |
| 834 |
| 720 |
| 586 |
| 498 |
| 438 |
| Finance costs | -37.9% | 4.6 | 6.8 | 5.23 | 9.12 | 6.9 | 9.1 |
| Depreciation and Amortization | 6.1% | 140 | 132 | 127 | 121 | 111 | 91 |
| Other expenses | 16.6% | 1,094 | 938 | 986 | 831 | 573 | 562 |
| Total Expenses | 9.1% | 3,262 | 2,991 | 2,844 | 2,380 | 1,920 | 1,764 |
| Profit Before exceptional items and Tax | 7.6% | 1,180 | 1,097 | 700 | 901 | 902 | 617 |
| Exceptional items before tax | - | 0 | 0 | 0 | 0 | 0 | -3.92 |
| Total profit before tax | 7.6% | 1,180 | 1,097 | 700 | 901 | 902 | 613 |
| Current tax | -7.2% | 258 | 278 | 144 | 171 | 217 | 168 |
| Deferred tax | -62.4% | 5.14 | 12 | -2.93 | 9.51 | 9.77 | 3.45 |
| Total tax | -9.3% | 263 | 290 | 141 | 181 | 226 | 172 |
| Total profit (loss) for period | 13.6% | 917 | 807 | 559 | 720 | 676 | 441 |
| Other comp. income net of taxes | -94% | -5.83 | -2.52 | -2.27 | 0.36 | -1.33 | -2.55 |
| Total Comprehensive Income | 13.2% | 911 | 805 | 556 | 720 | 674 | 439 |
| Earnings Per Share, Basic | 14.5% | 73.28 | 64.11 | 43.61 | 55.52 | 51.726667 | 33.7 |
| Earnings Per Share, Diluted | 14.6% | 73.25 | 64.06 | 43.61 | 55.52 | 51.726667 | 33.7 |
| 7.1% |
| 1,737 |
| 1,622 |
| 1,353 |
| 1,377 |
| 1,389 |
| 1,400 |
| Capital work-in-progress | -17.1% | 146 | 176 | 349 | 256 | 205 | 209 |
| Investment property | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-current investments | 0% | 43 | 43 | 44 | 37 | 43 | 43 |
| Loans, non-current | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total non-current financial assets | -4% | 49 | 51 | 52 | 46 | 54 | 54 |
| Total non-current assets | 4.4% | 2,064 | 1,978 | 1,853 | 1,776 | 1,743 | 1,753 |
| Total assets | 9.9% | 5,003 | 4,554 | 4,412 | 4,217 | 4,049 | 4,305 |
| Total non-current financial liabilities | 12.5% | 28 | 25 | 22 | 24 | 24 | 26 |
| Provisions, non-current | -51.9% | 39 | 80 | 67 | 40 | 23 | 24 |
| Total non-current liabilities | -13.8% | 188 | 218 | 204 | 174 | 152 | 150 |
| Total current financial liabilities | 4.9% | 558 | 532 | 502 | 514 | 447 | 859 |
| Provisions, current | 0% | 23 | 23 | 21 | 18 | 12 | 14 |
| Current tax liabilities | 131.2% | 38 | 17 | 58 | 37 | 57 | 11 |
| Total current liabilities | -3.4% | 687 | 711 | 678 | 629 | 541 | 908 |
| Total liabilities | -5.8% | 875 | 929 | 882 | 804 | 693 | 1,058 |
| Equity share capital | 0% | 25 | 25 | 25 | 25 | 25 | 25 |
| Total equity | 13.9% | 4,128 | 3,625 | 3,530 | 3,414 | 3,356 | 3,246 |
| Total equity and liabilities | 9.9% | 5,003 | 4,554 | 4,412 | 4,217 | 4,049 | 4,305 |
| 4 |
| 4.87 |
| 0.22 |
| 0.3 |
| - |
| - |
| Net Cashflows from Operations | 35.3% | 1,336 | 988 | 862 | 736 | - | - |
| Income taxes paid (refund) | 12% | 282 | 252 | 126 | 193 | - | - |
| Other inflows (outflows) of cash | - | 0 | 0 | 0 | 0.02 | - | - |
| Net Cashflows From Operating Activities | 43.5% | 1,054 | 735 | 736 | 542 | - | - |
| Cash payment for investment in partnership firm or association of persons or LLP | - | 6.25 | 0 | 0 | 25 | - | - |
| Proceeds from sales of PPE | -101.4% | 0.85 | 12 | 0.57 | 18 | - | - |
| Purchase of property, plant and equipment | 107.9% | 317 | 153 | 176 | 147 | - | - |
| Dividends received | -25% | 22 | 29 | 35 | 22 | - | - |
| Interest received | 29.7% | 49 | 38 | 25 | 12 | - | - |
| Other inflows (outflows) of cash | -101.8% | -0.13 | 0.44 | 4.35 | 27 | - | - |
| Net Cashflows From Investing Activities | -437.1% | -349.6 | 105 | -501.31 | -66.04 | - | - |
| Proceeds from issuing shares | - | 0.01 | 0 | 0 | 0 | - | - |
| Payments to acquire or redeem entity's shares | -9.3% | 353 | 389 | 1.44 | 354 | - | - |
| Payments of lease liabilities | -8.3% | 12 | 13 | 12 | 14 | - | - |
| Dividends paid | -45.7% | 349 | 642 | 90 | 82 | - | - |
| Interest paid | -83.1% | 1.41 | 3.42 | 1.76 | 6.52 | - | - |
| Net Cashflows from Financing Activities | 31.7% | -715.71 | -1,047.7 | -105.12 | -457.32 | - | - |
| Effect of exchange rate on cash eq. | -260.8% | -1.67 | 0.26 | -0.84 | 0.95 | - | - |
| Net change in cash and cash eq. | 93.2% | -13.18 | -207.07 | 129 | 20 | - | - |
Analyst / Investor Meet • 12 Jan 2026 Pls find enclosed Investor Call Intimation |